Exhaustive Study on Implantable Neurostimulators Market 2021 | Strategic Assessment by Top Players (NeuroPace, NeuroSigma, Medtronic, Boston Scientific) | Forecast to 2025

A market study ”Global Implantable Neurostimulators Market” examines the performance of the Global Implantable Neurostimulators Market 2021. It encloses an in-depth Research of the Implantable Neurostimulators Market state and the competitive landscape globally. This report analyzes the potential of Implantable Neurostimulators Market in the present and the future prospects from various angles in detail.

Global Implantable Neurostimulators Market Overview:

The Global Implantable Neurostimulators Market research report is the investigation arranged by investigators, which contain a point by point examination of drivers, limitations, and openings alongside their effect on the Implantable Neurostimulators Market development (2021 - 2025).

The most important key factors driving the growth of the Global Implantable Neurostimulators Market are rapid growth in adoption of neurostimulation devices by physicians and the rising prevalence of chronic neuro-muscular disorders. However, the discomfort caused by the invasive surgical procedure for implanting the device which is also expensive is a major restraint for the market. The trend of outsourcing medical devices is being adopted by manufacturers, propelling the market globally.

Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/235619 .

The Global Implantable Neurostimulators Market is segmented in the basis of Type, Application and Region. Based on the Type, the Global Implantable Neurostimulators Market is classified into Deep Brain Stimulators, Spinal Cord Stimulators, Vagal Nerve Stimulators, Sacral Nerve Stimulators, and others. On the b basis of Application, the Global Implantable Neurostimulators Market is sub-segmented into Parkinson’s disease, Epilepsy, Pain, and Others.

Industry Updates:

Medtronic (March 04, 2021) - Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation - Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (AF). The first procedure in the PULSED AF pivotal trial was performed this week at Southcoast Health by Nitesh Sood, M.D., Fall River, Massachusetts; the second procedure was performed by Arnoldas Giedrimas, M.D., also at Southcoast Health. The PULSED AF Trial is the first global, pre-market, multi-center clinical study with IDE approval aimed to establish the safety and efficacy of the PulseSelect System.

Developed exclusively at Medtronic, the PulseSelect System delivers pulsed electric fields through an ablation catheter designed specifically to interrupt irregular electrical pathways in the heart that trigger atrial fibrillation. However, unlike traditional methods of ablation that heat (radio frequency ablation) or cool (cryoablation) the atrial tissue, the PulseSelect System uses a non-thermal approach and preferentially targets heart tissue with the goal of avoiding unwanted injury to surrounding structures, a risk of current ablation technologies.

"Based on the results we've experienced with the pilot trial, we are entering a new era for AF ablation techniques with this novel energy source," said Atul Verma, M.D., electrophysiologist and head of arrhythmia services at Southlake Regional Health Centre in Newmarket, Canada and the principal investigator (PI) for the PULSED AF study. "We are excited to begin the pivotal stage of the PULSED AF study and generate a larger body of clinical evidence to support the safety and benefits of pulsed field ablation."

Atrial fibrillation is one of the most common and undertreated heart rhythm disorders, affecting more than 37 million people worldwide. The disease involves an irregular quivering or rapid heart rhythm in the upper chambers of the heart. A heart in AF beats significantly faster than one in normal rhythm. AF is a progressive disease that gets worse over time and can increase the risk for stroke and related heart problems.

The PULSED AF trial is a prospective, non-randomized, multi-center clinical trial that will enroll up to 500 patients who will be treated with the PulseSelect System across as many as 50 sites in the U.S., Canada, Europe, and Australia. PULSED AF is designed to evaluate the safety and efficacy of the PulseSelect System for the treatment of AF in adult patients with a history of drug refractory, recurrent and symptomatic paroxysmal or persistent AF. Patients will be assessed at six and 12 months.

Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Implantable Neurostimulators Market Report 2021” @ https://www.businessindustryreports.com/buy-now/235619/single .

Top Leading Key Players in Global Implantable Neurostimulators Market: Medtronic, Boston Scientific, St. Jude Medical, Cyberonics, NeuroPace, Synapse Biomedical, NeuroSigma, EnteroMedics, ElectroCore Medical, Inspire Medical, NEUROS, SPR, IMTHERA, NEVRO and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

With the presence of a large pool of participants, the Global Implantable Neurostimulators Market is displaying a highly competitive business landscape, finds a new research report by Business Industry Reports (BIR). Medtronic, Boston Scientific, St. Jude Medical, Cyberonics, NeuroPace, Synapse Biomedical, NeuroSigma, EnteroMedics, ElectroCore Medical, Inspire Medical, NEUROS, SPR, etc. are some of the key vendors of Implantable Neurostimulators across the world. These players across Implantable Neurostimulators Market are focusing aggressively on innovation, as well as on including advanced technologies in their existing products.

Region segment: This report is segmented into several key regions, with sales, revenue, market share (%) and growth Rate (%) of Implantable Neurostimulators in these regions, from 2013 to 2025 (forecast), covering: North America, Europe, Asia Pacific, Middle East & Africa and South America

Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/235619 .

Major Points in Table of Contents:

Global Implantable Neurostimulators Market Report 2021

1 Implantable Neurostimulators Product Definition

2 Global Implantable Neurostimulators Market Manufacturer Share and Market Overview

2.1 Global Manufacturer Implantable Neurostimulators Shipments

2.2 Global Manufacturer Implantable Neurostimulators Business Revenue

2.3 Global Implantable Neurostimulators Market Overview

3 Manufacturer Implantable Neurostimulators Business Introduction

3.1 Medtronic Implantable Neurostimulators Business Introduction

3.2 Boston Scientific Implantable Neurostimulators Business Introduction

3.3 St. Jude Medical Implantable Neurostimulators Business Introduction

3.4 Cyberonics Implantable Neurostimulators Business Introduction

3.5 NeuroPace Implantable Neurostimulators Business Introduction

3.6 Synapse Biomedical Implantable Neurostimulators Business Introduction

………………. Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is a digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that hold the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic, and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.